Skip to main content
Retrospective study of 374 newly diagnosed microscopic polyangiitis (MPA) pts - 97 (26%) had severe infections w/in 6 mo

Dr. John Cush RheumNow

3 months 2 weeks ago
Retrospective study of 374 newly diagnosed microscopic polyangiitis (MPA) pts - 97 (26%) had severe infections w/in 6 mos - signif higher risk w/ high dose prednisone & chronic lung Dz. most common: bacterial (43%) & lung infx https://t.co/XXAxUZw7kx https://t.co/atK8Ob9zyQ
Modest Benefits with AI Scribes on EHR Documentation

Documenting patient visits in the EHR is essential to care, but a

Dr. John Cush RheumNow

3 months 2 weeks ago
Modest Benefits with AI Scribes on EHR Documentation Documenting patient visits in the EHR is essential to care, but a major contributor to clinician burnout. AI-enabled ambient documentation (“AI scribes”) can auto-generate draft clinical notes for clinician review. They may https://t.co/6HaUwpFYLC
Retrospective clinicopathologic review of 170 AORTIC surgical pathology cases (2009-16) - showed 87% w/ atherosclerosis,

Dr. John Cush RheumNow

3 months 2 weeks ago
Retrospective clinicopathologic review of 170 AORTIC surgical pathology cases (2009-16) - showed 87% w/ atherosclerosis, 13% aortitis/periaortitis and 2.4% atherosclerosis w/ excessive inflammation. Lymphoplasmacytic inflammation was most common w/ aortitis/periaortitis. https://t.co/CuP30dqRQU
152 pts w/ immune thrombocytopenia (ITP) Rx in DBRPCT of Ianalumab (9mg or 3 mg/kg) or PBO q mo x 4 mos (all on Eltrombo

Dr. John Cush RheumNow

3 months 2 weeks ago
152 pts w/ immune thrombocytopenia (ITP) Rx in DBRPCT of Ianalumab (9mg or 3 mg/kg) or PBO q mo x 4 mos (all on Eltrombopag). Time to Rx failure signif longer w/ ianalumab. Stable 6 month response better w/ 9-mg group vs PBO (62% vs 39%; P=0.045) https://t.co/J04trYAwLu https://t.co/Alm8V2SAXn
Litifilimab in Cutaneous Lupus Erythematosus

Biogen has announced positive results of their Phase 2 study, evaluating

Dr. John Cush RheumNow

3 months 2 weeks ago
Litifilimab in Cutaneous Lupus Erythematosus Biogen has announced positive results of their Phase 2 study, evaluating litifilimab in patients with active cutaneous lupus erythematosus (CLE), presented at the recent American Academy of Dermatology (AAD) Annual Meeting. https://t.co/3Wb6iFViOm
The American College of Rheumatology (ACR) today thanked lawmakers in the U.S. House of Representatives for introducing the bipartisan Provider Reimbursement Stability Act of 2025 (H.R. 8163), legislation designed to stabilize Medicare payments for physicians and protect patient access to care.
An NEJM study has shown that glucocorticoids provide no added benefit when added to standard primary treatment in Kawasaki disease patients.
Arthritis Research & Therapy has published an overarching review of Still's disease - claiming it to be a single acquired and complex autoinflammatory disease in which both pediatric and adult forms share core pathogenic mechanisms, genetic associations and clinical presentations, with minor differences between children and adults who are afflicted.
A 2026 Physician Survey to assess artificial intelligence and its use in Medical Practice has been published and follows earlier surveys around adoption and use. This is the third in a series of longitudinal surveys (prior waves 2023, 2024), enabling meaningful trend analysis. AI adoption has more than doubled in three years and physician sentiment shifting decisively toward cautious optimism.
Screening High Risk Myositis Patients for Cancer

An Italian retrospective study of 411 idiopathic inflammatory myopath

Dr. John Cush RheumNow

3 months 2 weeks ago
Screening High Risk Myositis Patients for Cancer An Italian retrospective study of 411 idiopathic inflammatory myopathies (IIM) patients applied IMACS criteria to assess the risk of cancer and found significantly more cancers in those at high risk. https://t.co/AHvC5xfsCr https://t.co/Bd4VMRX9PU
Retrospective observational study of IPAF (ILD w/ autoimmune) pts - from Mt Sinai ILD registry 791 - 14 Rx w/ rituximab

Dr. John Cush RheumNow

3 months 2 weeks ago
Retrospective observational study of IPAF (ILD w/ autoimmune) pts - from Mt Sinai ILD registry 791 - 14 Rx w/ rituximab vs 19 not. Betw group outcomes same: PFTs, O2 use, Infx, Resp admissions, mortality. RTX group recv more immunosuppressives. https://t.co/sle4a0JOFL https://t.co/SyhK12KhHY
A LESSON FOR GC OVERUSE: Inappropriate PPI use was Twice as successful w/ reduced w/ GP & Pt-facing intervention (15

Dr. John Cush RheumNow

3 months 2 weeks ago
A LESSON FOR GC OVERUSE: Inappropriate PPI use was Twice as successful w/ reduced w/ GP & Pt-facing intervention (15 vs 7%) vs usual care or GP-only intervention. Study of 1498 GPs, 34K pts https://t.co/4cxoeanAK8 https://t.co/FdfUdST40o
Opioids Down, Gabapentins Up

The number of U.S. patients prescribed long-term opioid therapy declined from 2015 to 202

Dr. John Cush RheumNow

3 months 2 weeks ago
Opioids Down, Gabapentins Up The number of U.S. patients prescribed long-term opioid therapy declined from 2015 to 2023, but co-prescribing of opioids with gabapentinoids increased, prescription data showed. https://t.co/iXEUfR18Is https://t.co/6DCUvGAW6N
Top Four and More (4.10.2026)

Dr. Jack Cush reviews the news and journal reports from RheumNow this week - including h

Dr. John Cush RheumNow

3 months 2 weeks ago
Top Four and More (4.10.2026) Dr. Jack Cush reviews the news and journal reports from RheumNow this week - including his top four favorite subjects. https://t.co/TUPky5m1Mo https://t.co/QRgh9SqcOF
×